脂質體阿黴素市場規模、佔有率和成長分析（按產品類型、應用、分銷管道和地區）- 2025-2032 年產業預測

2023 年全球脂質體阿黴素市場規模價值為 12 億美元，預計將從 2024 年的 12.8 億美元成長到 2032 年的 21 億美元，預測期間（2025-2032 年）的複合年成長率為 6.4%。

由於肉瘤發病率的上升以及該藥物在治療乳腺癌、卵巢癌和卡波西氏肉瘤等各種癌症中的應用，脂質體阿黴素市場正在經歷強勁成長。這種脂質體包裹的化療溶液受益於現代醫療保健的進步、醫療成本的上升以及患者對治療方案的認知的提高。儘管學名藥的競爭和 FDA 的嚴格核准程序仍是挑戰，但由於公共和私營部門的投資增加，預計整體市場將會擴大。此外，肝細胞癌發病率和存活率的上升，以及對傳統治療無反應的患者對有效替代療法的需求不斷成長，進一步刺激了對脂質體阿黴素的需求，預計這將推動市場在未來幾年大幅成長。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局
• 專利分析

脂質體阿黴素市場規模（按產品類型和複合年成長率） (2025-2032)

• 市場概況
• 脂質體
• Doxil
• Mio 套裝

脂質體阿黴素市場規模（按應用和複合年成長率） (2025-2032)

• 市場概況
• 乳癌
• 卵巢癌
• 多發性骨髓瘤
• 卡波西氏肉瘤
• 其他癌症

脂質體阿黴素市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局

脂質體阿黴素市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Johnson & Johnson（USA）
• Sun Pharmaceutical Industries Ltd.（India）
• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• Cipla Inc.（India）
• Cadila Pharmaceuticals（India）
• SRS Pharmaceuticals Pvt. Ltd.（India）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Gilead Sciences, Inc.（USA）
• Baxter International Inc.（USA）
• Novartis AG（Switzerland）
• F. Hoffmann-La Roche AG（Switzerland）
• Bristol-Myers Squibb Company（USA）
• Mylan NV（USA）
• Sanofi SA（France）
• Eli Lilly and Company（USA）
• GlaxoSmithKline plc（UK）
• AstraZeneca plc（UK）
• Amgen Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）

結論和建議

Global Liposomal Doxorubicin Market size was valued at USD 1.2 billion in 2023 and is poised to grow from USD 1.28 billion in 2024 to USD 2.1 billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032).

The liposomal doxorubicin market is experiencing robust growth driven by the rising incidence of sarcoma and the drug's use in treating various cancers such as breast, ovarian, and Kaposi sarcoma. This chemotherapy solution, encapsulated in liposomes, benefits from modern healthcare advancements, increased healthcare expenditures, and heightened patient awareness regarding treatment options. While competition from generic medications and stringent FDA approval processes pose challenges, overall market expansion is anticipated due to growing investment from both public and private sectors. Additionally, the escalating need for effective alternatives for patients unresponsive to traditional treatments, alongside the rising incidence and survival rates of hepatocellular carcinoma, further stimulates demand for liposomal doxorubicin, positioning the market for substantial growth in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liposomal Doxorubicin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liposomal Doxorubicin Market Segments Analysis

Global Liposomal Doxorubicin Market is segmented by Product Type, Application, Distribution Channel and region. Based on Product Type, the market is segmented into Lipodox, Doxil and Myocet. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, Multiple Myeloma, Kaposi's Sarcoma and Other Cancers. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liposomal Doxorubicin Market

The Global Liposomal Doxorubicin market is predominantly driven by its application in the treatment of breast cancer, a disease that is rapidly escalating in prevalence across the globe. The surge in innovative formulations has significantly enhanced the drug's appeal and adoption for breast cancer therapy. Several other factors are expected to propel market growth in the coming years, including a rising demand for targeted therapies, increased utilization of chemotherapy, and heightened investments from private sectors focused on this treatment. Additionally, robust government support for the healthcare industry plays a vital role in advancing the market's global expansion.

Restraints in the Global Liposomal Doxorubicin Market

The global liposomal doxorubicin market could face limitations due to potential adverse effects associated with the medication. Patients may experience various complications such as an increased risk of infections, difficulty in breathing, pallor, unexplained bruising, frequent nosebleeds, fatigue, and weakness both prior to and following treatment. Additionally, symptoms such as painful red or peeling skin on the hands and feet, significant weight loss, diarrhea, and generalized weariness may arise. These side effects could result in hesitancy among patients and healthcare providers, ultimately restraining the market's growth and acceptance in the treatment landscape.

Market Trends of the Global Liposomal Doxorubicin Market

The Global Liposomal Doxorubicin market is witnessing significant growth, driven primarily by the increasing incidence of breast cancer, which accounts for one in four female cancer diagnoses globally, according to the International Agency for Research on Cancer (IARC). As liposomal formulations enhance the therapeutic efficacy and reduce the cardiotoxicity associated with conventional doxorubicin, they are gaining traction among oncologists and patients alike. Innovations in drug delivery systems, coupled with rising healthcare expenditures and a surge in awareness regarding targeted cancer therapies, position liposomal doxorubicin as a preferred choice in chemotherapeutic regimens, effectively meeting the growing demand for safer and more effective cancer treatments worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Liposomal Doxorubicin Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Lipodox
• Doxil
• Myocet

Global Liposomal Doxorubicin Market Size by Application & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Ovarian Cancer
• Multiple Myeloma
• Kaposi's Sarcoma
• Other Cancers

Global Liposomal Doxorubicin Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Liposomal Doxorubicin Market Size & CAGR (2025-2032)

• North America (Product Type, Application, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Pharmaceuticals (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SRS Pharmaceuticals Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations